About one in nine Canadians who are infected with hepatitis C spend time in a correctional facility each year. With high rates of current injection drug use and needle sharing, this population may account for a large proportion of new infections. Any national strategy to address hepatitis C should include a focus on persons in correctional facilities, and should build on existing evidence regarding primary, secondary and tertiary prevention.
I
n light of the large burden of disease and costs associated with hepatitis C infection in Canada, 1, 2 there is an urgent need for Canada to develop a comprehensive strategy for hepatitis C control. 3 Such a strategy should include a focus on high-risk populations in which hepatitis C is prevalent, and in which there are opportunities for primary, secondary and tertiary prevention.
In this article, we present evidence from the literature to show that persons who spend time in correctional facilities represent a large proportion of the cases of hepatitis C in Canada, and that time in custody may serve as an opportunity to access prevention initiatives. A focus on this population could contribute to the overall control of hepatitis C in Canada.
Burden of hepatitis C in persons in correctional facilities in Canada A recent analysis from the Public Health Agency of Canada determined that 24.0% of persons in federal custody and 23.3% of persons in provincial or territorial custody are anti-HCV positive, which means that they have ever been infected with or exposed to hepatitis C. 6 Table 1 . This means that between one in eight and one in nine of the estimated 220,697 to 244,836 Canadians with chronic hepatitis C 6 spend time in a correctional facility in Canada each year. Persons in correctional facilities report high rates of recent injection drug use and needle sharing, both in custody and in the community. [7] [8] [9] [10] [11] As these risk behaviours are associated with hepatitis C transmission, persons who spend time in correctional facilities are likely at risk of incident infection if they are not already infected, or of transmitting infection to others if they are already infected; in this way, they are likely responsible for a significant proportion of new cases. This contrasts with other groups that have a high prevalence of hepatitis C, such as those born between 1950 and 1964, 6 who are less likely to be currently involved in behaviours that are associated with hepatitis C transmission.
Strategies to address hepatitis C in persons in correctional facilities
Hepatitis C prevention in persons in correctional facilities could involve providing them with primary, secondary and tertiary prevention measures while they are in custody, or linking them with community-based prevention programs upon their release. Time in custody may be a unique opportunity for public health For primary prevention, prison needle exchange has been shown to prevent the transmission of bloodborne infections in custody, 15, 16 but is not currently available in any correctional facilities in Canada. Bleach is available in some jurisdictions as a means to decontaminate syringes, however, given the lack of high-quality evidence of the effectiveness of bleach programs, they are considered "second-line" to needle and syringe programs. 17 Research from community settings reveals that opioid substitution therapy and drug treatment prevent hepatitis C infection in persons who inject drugs, 18, 19 and these treatments could be initiated in custody or upon release. For secondary prevention, systematic screening for hepatitis C is provided in federal facilities, but not in most provincial and territorial facilities. Innovative strategies such as the use of dried blood spot testing have been shown to be feasible and acceptable in correctional settings in other countries. 20, 21 For tertiary prevention, treatment of hepatitis C could prevent the sequelae of chronic hepatitis C infection and prevent further transmission. Currently, hepatitis C treatment is available in federal facilities, however, in many provincial and territorial facilities, it is only available to those who were already undergoing treatment in the community; individuals cannot initiate treatment. Evidence from persons in federal custody in British Columbia demonstrates that treatment is effective, leading to sustained virological response rates that are comparable to the rates in non-incarcerated populations, 22 and that continuation of treatment after release is feasible, 23 though high re-infection rates suggest that treatment should be coupled with other prevention initiatives. 24 
CONCLUSIONS
We estimate that more than one in nine persons with hepatitis C in Canada spend time in a correctional facility each year. These persons may be responsible for ongoing transmission of infection, based on the high prevalence of injection drug use. Time in custody presents an opportunity for health care and public health services to identify and manage a significant proportion of hepatitis C cases in Canada and to prevent new infections. As recommended by the World Health Organization, public health and prison health systems should collaborate in the development and implementation of evidence-based programs in correctional facilities and link persons to community-based programs upon their release. 25 A focus on persons in correctional facilities is likely to significantly impact the burden of disease of hepatitis C and to improve hepatitis C control in Canada. 
